Abstract:Abstract: Chimeric antigen receptor T-cells, known as CAR-T cells, represent a promising breakthrough in the realm of adoptive cell therapy. These T-cells are genetically engineered to carry chimeric antigen receptors that specifically target tumors. They have achieved notable success in the treatment of blood-related cancers, breathing new life into this field of medical research. However, numerous obstacles limit chimeric antigen receptors T-cell therapy's efficacy, such as it cannot survive in the body long. It is prone to fatigue and exhaustion, leading to difficult tumor elimination and repeated recurrence, affecting solid tumors and hematological malignancies. The challenges posed by solid tumors, especially in the context of the complex solid-tumor microenvironment, require specific strategies. This review outlines recent advancements in improving chimeric antigen receptors T-cell therapy by focusing on the chimeric antigen receptors protein, modifying T-cells, and optimizing the interaction between T-cells and other components within the tumor microenvironment. This article aims to provide an extensive summary of the latest discoveries regarding CAR-T cell therapy, encompassing its application across various types of human cancers. Moreover, it will delve into the obstacles that have emerged in recent times, offering insights into the challenges faced by this innovative approach. Finally, it highlights novel therapeutic options in treating hematological and solid malignancies with chimeric antigen receptors T-cell therapies.

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

CAR-T Cell Therapy for Hematological Malignancies: History, Status and Promise

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Advances in CAR-T-cell therapy in T-cell malignancies

Application of CAR-T Cell Immunotherapy in the Treatment of Hematological Malignancy

Progress on CAR-T Cell Therapy for Hematological Malignancies

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies

Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy

Advances in chimeric antigen receptor T cell therapy for treatment of hematological malignancies

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Current progress in CAR-T cell therapy for tumor treatment

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities

Current state of CAR-T therapy for T-cell malignancies

Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review

Current Progress in CAR-T Cell Therapy for Hematological Malignancies